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Abstract. 
Prompt diagnosis and effective treatment of acute malaria in pregnancy (MiP) is important for the mother and fetus; 
data on health-care provider adherence to diagnostic guidelines in pregnancy are limited. From September to 
November 2013, a cross-sectional survey was conducted in 51 health facilities and 39 drug outlets in Western 
Kenya. Provider knowledge of national diagnostic guidelines for uncomplicated MiP were assessed using 
standardized questionnaires. The use of parasitologic testing was assessed in health facilities via exit interviews with 
febrile women of childbearing age and in drug outlets via simulated-client scenarios, posing as pregnant women or 
their spouses. Overall, 93% of providers tested for malaria or accurately described signs and symptoms consistent 
with clinical malaria. Malaria was parasitologically confirmed in 77% of all patients presenting with febrile illness at 
health facilities and 5% of simulated clients at drug outlets. Parasitological testing was available in 80% of health 
facilities; 92% of patients evaluated at these facilities were tested. Only 23% of drug outlets had malaria rapid 
diagnostic tests (RDTs); at these outlets, RDTs were offered in 17% of client simulations. No differences were 
observed in testing rates by pregnancy trimester. The study highlights gaps among health providers in diagnostic 
knowledge and practice related to MiP, and the lack of malaria diagnostic capacity, particularly in drug outlets. The 
most important factor associated with malaria testing of pregnant women was the availability of diagnostics at the 
point of service. Interventions that increase the availability of malaria diagnostic services might improve malaria 
case management in pregnant women. 
INTRODUCTION 
Since 2010, Kenya Ministry of Health (MoH) malaria diagnostic guidelines have 
recommended universal parasitological testing, via microscopy or malaria rapid diagnostic test 
(RDT), of febrile patients across all demographic groups, including pregnant women.
1,2
 
Antimalarial treatment on the basis of clinical malaria signs and symptoms should only be 
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considered in situations where a parasitological diagnosis is not available, particularly in 
vulnerable populations such as pregnant women.
2
 
Malaria in pregnancy (MiP) can have devastating consequences for the woman and fetus, 
including maternal anemia, fetal loss, intrauterine growth retardation, premature delivery, and 
low birth weight (LBW) with increased risk for neonatal death.
3
 The Kenya MoH recommends 
that pregnant women receive prompt and effective diagnosis and treatment of malaria with a safe 
drug to prevent adverse consequences. Treatment with non-recommended drugs, whether 
antimalarials, antibiotics, or other drugs, can have adverse consequences for the woman. With 
the added risk to the fetus, it is particularly important to avoid unnecessary drug exposures 
during pregnancy.
4,5
 
Kenya introduced malaria RDTs for malaria diagnosis in 2006 in low-transmission areas and 
nationally in late 2012. The 2010 Kenya National Malaria Strategic Plan goal was to have 
universal availability of malaria diagnostic capacity, defined as having either functional 
microscopy or RDTs, by 2013.
1,6
 By mid-2013, 90% of health facilities nationally had the 
capacity to provide a malaria parasitological diagnosis and 70% had RDTs.
7
 Although malaria 
testing rates among febrile patients increased by 34% from a baseline of 24% in 2010, only 58% 
of patients with suspected malaria were tested at health facilities with diagnostic capacity.
7
 
Provider reliance on clinical diagnosis, rather than parasitological diagnosis, with poor 
adherence to treatment policy has been consistently observed throughout malaria-endemic 
countries.
8
 Malaria diagnosis in pregnant women also has been suboptimal, particularly in the 
first trimester.
8
 With women of childbearing age (WOCBA) representing about 25% of the total 
population and pregnant women representing approximately 4% of the population in many 
malaria-endemic countries, including Kenya, understanding provider diagnostic behavior toward 
women of reproductive age and pregnant women is important to optimizing case management 
and minimizing potential harmful drug exposures. In Kenya, studies have estimated that 17–83% 
of persons with fever are treated first with medicine purchased from private-sector drug outlets 
(registered pharmacies, drug shops/chemists, or general shops) rather than in health facilities.
9–11
 
Therefore, a cross-sectional study was conducted to assess health-care provider and drug-outlet 
dispenser behaviors and knowledge of malaria diagnostic guidelines for pregnant women in a 
malaria-endemic region of western Kenya in 2013. 
METHODS 
Study site & sampling. 
The study was conducted from September to November 2013 in rural Siaya County in 
western Kenya, where malaria transmission is perennial and holoendemic. The study area 
included the Kenya Medical Research Institute (KEMRI) and U.S. Centers for Disease Control 
and Prevention (CDC) Research and Public Health Collaboration’s Health and Demographic 
Surveillance System (HDSS). The KEMRI-CDC HDSS platform has been detailed previously.
12
 
At the time the study was conducted, approximately 20% of pregnant women were parasitemic 
by polymerase chain reaction at first antenatal clinic visit
13
 and 9% of women delivering in Siaya 
District Hospital had microscopically confirmed placental malaria.
14
 
Adherence to the Kenya national malaria diagnostic guidelines was observed by 1) exit 
interviews with women aged 18–49 years, including pregnant women, being treated for febrile 
illness at all participating health facilities within the study area and 2) use of a simulated-client 
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approach within randomly sampled drug outlets.
1,15,16
 Knowledge of diagnostic guidelines and 
self-reported diagnosing behavior for MiP was assessed by structured questionnaires 
administered to health-care providers and drug dispensers. The assessments were conducted after 
completion of the provider- and dispenser-practice component to avoid influencing actual 
practice. The data were collected as part of a broader study to assess overall provider knowledge 
and adherence to MiP case management guidelines. Detailed methods have been published 
elsewhere.
17
 
Health facility selection. 
All public and private health facilities, including hospitals, health centers, or dispensaries, in 
the KEMRI-CDC HDSS study area and within a 5-km radius surrounding the HDSS were 
assessed for eligibility. Facilities were eligible if they provided outpatient care to WOCBA and 
the facility supervisor consented to participate. Facilities with other ongoing malaria studies were 
excluded. 
Drug outlets selection. 
During September to October, 2013, a census was conducted of all drug outlets, including 
registered pharmacies, unregistered (i.e., informal) drug shops/chemists, and general shops, 
selling antimalarial drugs within the HDSS border; detailed methods have been published 
elsewhere.
18
 Malaria RDT availability was 10% in surveyed drug outlets; 84% of drug outlets 
had never stocked RDTs.
18
 Of 181 identified drug outlets, 27 home-based shops were excluded 
because a simulated-client approach was not feasible in this setting, and 152 consented for future 
participation in the knowledge and practice assessment. Among the 152 consenting drug outlets, 
39 were selected for participation by simple random sampling; the sample size allowed 
estimation of the proportion of providers with adequate knowledge with 14% precision at 80% 
power, assuming that 45% of providers had adequate knowledge and prescribing practices.
19
 
Data collection. 
Exit interviews in health facilities. 
Patients were assessed for eligibility after completing a provider consultation in either the 
outpatient department or antenatal care clinic and receiving all prescribed tests and medications. 
Exit interviews were conducted with consenting patients after a standard format. Pregnancy 
status was based on patients’ self-report and is defined as: 1) WOCBA who could potentially be 
pregnant; 2) women in first trimester (up to and including 14 weeks); and 3) women in the 
second or third trimester of pregnancy (15 weeks and beyond); gestational age and trimester 
were calculated from date of self-reported last menstrual period. In cases where an antimalarial 
contraindicated for pregnancy had been prescribed, the incorrect medication was replaced with 
the recommended treatment by the study clinician. Health providers were not made aware of 
these changes until after completion of the study. 
Simulated clients in drug outlets. 
The simulated-client or mystery-client approach was used to assess diagnostic practice.
15,16
 
Trained female study staff presented as either WOCBA or in early pregnancy and male staff 
presented as the husband of a WOCBA or woman in the third trimester of pregnancy; all three 
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scenarios (WOCBA, early pregnancy, and late pregnancy) were simulated at each outlet. A 
single dispenser-client simulation had the potential to include both nonpregnant and pregnant 
scenarios. Study staff members were not to disclose pregnancy status unless asked by the 
dispenser. If dispensers failed to assess pregnancy status, the simulated clients disclosed 
pregnancy status after receiving medication(s). The pregnancy scenario was then assessed based 
on any changes in practice made after pregnancy status disclosure. 
Provider surveys in health facilities & drug outlets. 
Immediately after the completion of exit interviews and 1 week after client simulations, a 
structured questionnaire was administered to providers and dispensers to assess knowledge and 
diagnostic practice. One to two providers per health facility (dependent on number of staff 
treating WOCBA and pregnant women) and one dispenser per drug outlet was interviewed; 
provider and dispenser selection was based on whether the provider treated WOCBA and 
availability at time of interview. 
Definitions. 
After the 2010 Kenya National Malaria Treatment Guidelines
1
 and 2010 World Health 
Organization Malaria Treatment Guidelines,
2
 correct practice was defined as the use of 
parasitological testing (either microscopy or malaria RDT), or when testing was unavailable, 
accurate description of symptoms consistent with clinical malaria (i.e., fever, chills, headache, 
vomiting, body aches, and general malaise). Adequate knowledge was defined as both an 
accurate description of malaria signs and symptoms and the requirement for parasitological 
testing for malaria diagnosis. Criteria for having performed a diagnostic assessment were if the 
dispenser offered a malaria RDT, asked if a malaria RDT or microscopy had been previously 
performed, or asked about clinical malaria symptoms. 
Data management & analysis. 
The provider survey data were collected by personal digital assistant, and simulated-client 
and exit interview data were collected on scannable forms. All analysis was performed with SAS 
9.3 (SAS Institute, Cary, NC). Statistical significance of categorical variables was assessed by 2 
or Fisher exact tests with a significance level of P  0.05. The proportion of providers who were 
adequately assessed for malaria was calculated, accounting for clustering by facility. Logistic 
regression models to identify significant (P  0.05) predictors of malaria diagnostic knowledge 
were developed at the individual-provider level, accounting for clustering by facility. Intra-
cluster correlation at the facility level was accounted for in all analysis. 
Ethics. 
The study was approved by the ethical and institutional review boards of KEMRI 
(KEMRI/RES/7/3/1), Liverpool School of Tropical Medicine (#13.18), and Emory University. 
Centers for Disease Control and Prevention’s involvement was deemed non-engaged by the 
Human Research Protection Office. Written informed consent was obtained from all providers 
and patients before interviews; verbal informed consent regarding future participation in a MiP 
study to assess diagnosis and treatment was obtained from the dispenser during the drug-outlet 
census. 
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RESULTS 
After excluding nine health facilities because of ongoing studies, 52 facilities were eligible 
for the study; supervisors in 51 facilities (four hospitals, 19 health centers, and 28 dispensaries) 
consented to participate (Table 1).
18
 
Malaria in pregnancy diagnostic knowledge. 
A total of 112 providers and dispensers across 86 point-of-care facilities were surveyed; 75 
(67%) in health facilities and 37 (33%) in drug outlets. Of respondents, 44% were nursing staff, 
16% were clinical officers or physicians, 18% were pharmacists (inclusive of degree, diploma, 
and certificate holders), and 13% were shopkeepers; overall, 52% were female. 
Most (90%) providers reported suspecting malaria in patients presenting with fever; other 
clinical symptoms cited included headache (84%), vomiting (82%), body ache (67%), and chills 
(65%). Health-facility providers had significantly greater knowledge of clinical malaria 
symptoms compared with drug-outlet dispensers. Eighty-four percent of health-facility providers 
reported using parasitological testing (81% of providers reported using RDT and 70% reported 
using microscopy); 25% of those who did not use diagnostics reported always treating clinically 
versus regularly, sometimes, or never. In drug outlets where malaria diagnostics were not widely 
available, 30% reported always treating based on clinical symptoms, and 19% reported never 
treating based on clinical presentation alone. Among the 12 dispensers who reported using 
parasitological testing, 50% reported using microscopy and 75% reported using RDTs. Across all 
providers and dispensers surveyed, 93% exhibited correct malaria diagnosis knowledge, 
reporting that they used parasitological testing (microscopy or RDT) or, when testing/test results 
were unavailable, were able to describe signs and symptoms consistent with clinical malaria 
diagnosis (Table 2). 
Malaria diagnosis in health facilities. 
A total of 209 eligible patients were interviewed across 51 health facilities: 111 (53%) 
nonpregnant women, 22 (11%) women in first trimester, and 77 (37%) women in second and 
third trimesters (Table 1). Of the 209 women, 160 (77%) were tested for malaria using either 
RDT or microscopy. Eighty percent of health facilities had confirmed malaria testing capacity; 
160 (92%) patients were tested at these facilities. Hospitals and health centers had significantly 
higher testing rates than dispensaries (89% and 90% versus 64%, P = 0.02) (Table 3). Providers 
who had attended a malaria diagnostic training in the last 5 years were only one-fifth as likely to 
test for malaria (aOR = 0.2, 95% confidence interval 0.04–1.0, P = 0.05) (Table 4) as those who 
had not attended a training in the last 5 years. There was no difference in testing rates across 
pregnancy status (73% in first trimester, 79% in second/third trimester, and 76% in nonpregnant, 
P = 0.79), number of malaria symptoms at presentation (77% with zero to one symptoms versus 
75% for two or more symptoms, P = 0.66) or for public versus private facilities (75% versus 
91%, P = 0.11). 
Nearly 60% (28/49) of women who were not tested were seen in facilities that did not have 
malaria diagnostic capacity. Therefore, 90% of women were properly assessed for malaria 
according to facility diagnostic capacity (Table 3). Of the 151 patients (94%) who tested positive 
for malaria, 98% received an antimalarial; no reason was provided for not prescribing an 
antimalarial to the remaining malaria-positive patients, although all facilities had antimalarials 
available on the day of the survey.
17
 The three (100%) patients who tested negative for malaria 
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were incorrectly prescribed an antimalarial. There was no difference in antibiotic prescribing for 
patients who were tested for malaria compared with those who were clinically diagnosed. Before 
antimalarial prescription, 61% of providers asked patients if they had received previous 
treatment of the current malaria episode and only 16% asked about allergies to medications. 
Malaria diagnosis in drug outlets. 
A total of 77 simulated client dispenser encounters were completed at 39 drug outlets (Table 
1). In 5% of all interactions (2 [22%] registered pharmacy interactions, 1 [8%] informal drug 
outlet, and 1 [6%] general shop interaction), dispensers either offered an RDT or asked if one 
had previously been performed; there was no difference between simulations when the woman 
was the simulated client or when a male relative was the simulated client. Nine (23%) drug 
outlets had RDTs available (5 [56%] of registered pharmacies, 4 [31%] of informal drug outlets, 
and no general shops); at these facilities, RDTs were offered or inquired upon in the case of a 
relative in 17% of simulations. Thirty-three percent of dispensers asked about any symptoms; 
16% inquired about specific malaria symptoms. In 34% of all simulations, dispensers either 
asked about malaria symptoms or requested a prescription for an antimalarial before dispensing. 
A higher proportion of dispensers asked about malaria symptoms when interacting with female 
clients seeking treatment of themselves compared with male clients seeking treatment on behalf 
of a spouse (Table 5). Neither facility type nor recent MiP training were associated with 
diagnostic practice among drug outlets (Supplemental Table 1). 
Of 27 clients who were not sold an antimalarial despite presenting with malaria symptoms in 
the simulations, 17 (63%) were referred to a health facility. Eight (30%) did not receive an 
antimalarial because of a stock out; other reasons included refusal to dispense an antimalarial 
without a prescription, diagnostic test, or clinical evaluation. Before dispensing, only 16% of 
dispensers asked the simulated client if any previous treatment had been given for the current 
illness and only 5% asked about potential medication allergies. Antimalarial dosage and timing 
directions were given to 87% of simulated clients. 
DISCUSSION 
Overall, provider and dispenser knowledge of clinical malaria signs and symptoms was very 
high across health facilities and drug outlets. However, health facilities and drug outlets differed 
significantly when it came to both observed and self-reported malaria parasitological testing. In 
health facilities overall, just over three-quarters of women with symptoms were tested for 
malaria, but in facilities with diagnostic capacity, 92% were tested. In drug outlets overall, only 
5% of simulated clients were offered or asked about malaria testing results. In the few drug 
outlets with malaria RDTs, less than one-fifth of simulated clients were offered testing. No 
differences in parasitological testing rates by pregnancy status were observed in either health 
facilities or drug outlets. The findings suggest that the single largest factor contributing to 
malaria testing was access to diagnostics at the point of service. 
Sixty percent more pregnant women were tested for malaria at facilities in western Kenya 
compared with the national estimates of parasitological testing among the general population in 
2013 (92% versus 58%).
7
 Pregnant women were tested more despite lower availability of 
diagnostics (80%) in surveyed facilities in Siaya County compared with 90% nationally.
7
 These 
findings are consistent with a previous study at a provincial hospital in Garissa, northeastern 
Kenya, which cited high adherence to parasitological diagnosis among pregnant patients and 
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similar to 2013 diagnostic capacity and testing rates in neighboring Tanzania (80% and 63%, 
respectively).
20,21
 The high parasitological testing for malaria among pregnant women is 
encouraging; pregnant women might be more likely to be prioritized for testing, particularly in 
the HDSS area of Siaya County, which has been the site of numerous malaria interventions 
historically and likely resulted in increased awareness among health-care providers.
12
 The 
increased diagnostic capacity at health facilities due to the national RDT implementation, which 
started in late 2012, has certainly contributed to the high testing rates observed. From 2010 to 
2013, malaria microscopy capacity at the health-facility level was unchanged at 51%, whereas 
malaria RDT capacity increased from 8% to 70% nationally.
7
 
In Kenya, only registered health facilities are officially allowed to provide diagnostic testing, 
including malaria RDTs. Private-sector drug outlets, including registered pharmacies that are 
licensed to sell medications, are not licensed to provide point-of-service diagnostic testing.
18
 
Thus, diagnostic capacity in drug outlets was very low at the time of the study with less than 
one-quarter of drug outlets stocking malaria RDTs.
18
 Only one-quarter of surveyed drug outlets 
were registered pharmacies; most of the drug outlets in rural communities are unlicensed 
informal drug outlets and general shops. Despite not being licensed to sell medications, there is 
evidence that these informal drug outlets increased availability and affordability for quality-
assured artemisinin-combination therapy in rural communities.
22
 Furthermore, evidence from 
private-sector malaria RDT pilots across malaria-endemic countries, including Kenya, has 
demonstrated that the use of RDTs in drug shops can improve appropriate case management and 
is comparable to use in health facilities, particularly when coupled with the implementation of 
quality assurance systems and point-of-use guidance tools.
23
 In addition, the private-sector 
market in Kenya can sustain unsubsidized quality-assured mRDTs. Consumer and provider 
marketing of mRDTs in Kenya doubled the monthly sales, suggesting that awareness of mRDTs 
can build and sustain demand.
23
 These results are driving crucial changes in national policies and 
regulations to allow point-of-service diagnostic testing at registered pharmacies to improve 
malaria case management practices.
23–26
 Increased and sustained advocacy for updated policy 
surrounding licensing for quality-assured mRDTs in drug outlets, which are often the first point 
of care, is a necessary first step to increase diagnostic testing rates. 
No significant associations between pregnancy status and parasitological testing were 
observed in either health facilities or drug outlets, which is incongruous with recent meta-
analysis findings.
8
 Parasitological testing by pregnancy status was consistent across all facilities 
with diagnostic availability. Improving patient and customer access to malaria diagnostic testing 
through increased availability of malaria RDTs at health facilities and private-sector drug outlets 
is crucial to meeting national strategy targets for case management. Interestingly, neither malaria 
diagnostics nor MiP trainings were associated with increased testing in this study. Studies in 
Tanzania and Uganda have introduced behavior change interventions to support the use of 
malaria RDTs, including the use of feedback and motivational text messages, small group 
workshops, and ensuring availability of treatment algorithms and medications for non-malaria 
febrile illnesses.
27,28
 In addition, evidence from neighboring countries suggests that educational 
initiatives around the importance of malaria testing for both providers and the general public 
should be expanded.
26
 Intensive communication campaigns via television and radio mass media 
were an effective means to improve private-sector provider awareness and knowledge of malaria 
case management, particularly in areas comparable to western Kenya.
29
 Quality assurance 
systems that integrate routine reporting systems such as DHIS2 and FIND’s troubleshooting 
guide for mRDTs
30
 offer an opportunity to monitor and improve provider performance.
23
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All patients, including pregnant women, should receive malaria parasitological testing to 
ensure appropriate treatment and prevent complications. Although no differences in malaria 
testing were observed by pregnancy status, testing for malaria is particularly crucial for women 
in the first trimester of pregnancy. In health facilities, almost three-quarters of women in the first 
trimester of pregnancy were tested compared with only 5% of clients simulating a first-trimester 
pregnancy either by being asked for diagnostic test results or offered a diagnostic test in drug 
outlets. In the absence of diagnostic testing, pregnant women are at risk of being incorrectly 
diagnosed with malaria and not appropriately treated for other causes of febrile illness. In 
addition, incorrect diagnoses result in unnecessary treatment with an antimalarial, which has the 
potential to cause adverse events in the woman and threatens the efficacy of antimalarial drugs in 
the population. The only recommended treatment of uncomplicated malaria in first-trimester 
pregnant women is quinine. Artemisinin-combination therapies are presently not recommended 
during the first trimester of pregnancy because of limited available data on human exposures and 
the potential for teratogenicity.
31
 
Limitations and challenges. 
Correct diagnostic practice in patients evaluated in health facilities might have been 
overestimated; for 20% of health facilities, diagnostic capacity at the facility was not confirmed. 
These facilities were either health centers or dispensaries, which were assumed to not have 
malaria diagnostic capacity based on historical knowledge of them never having had microscopy 
or RDTs. Therefore, a clinical diagnosis of malaria in these facilities was considered correct. In 
addition, the type of parasitological test, microscopy or RDT, was not collected nor were they 
subjected to quality assurance to confirm a malaria diagnosis. Therefore, patients could have 
been misclassified. Because overdiagnosis is common for clinically- and microscopically 
diagnosed malaria in Kenya, the study likely overestimated correct diagnosis.
32,33
 Recall bias was 
minimized by conducting exit interviews directly after patient–clinician interaction. Rapid 
diagnostic test availability at the time of the study may have been negatively affected by the loss 
of 4.2 million RDTs in a central warehouse fire in early 2013, which resulted in widespread 
stock-outs and delayed integration of RDTs into the malaria community case management 
strategy.
34
 Last, the small number of drug outlets with malaria RDTs prevented stratification by 
facility type, limiting a more robust analysis. 
CONCLUSION 
Both provider and dispenser knowledge of clinical malaria signs and symptoms was very 
high across health facilities and drug outlets in Siaya County, western Kenya. Over three-
quarters of health facilities had malaria diagnostic capacity and almost all pregnant women with 
suspected malaria had parasitological testing before treatment. However, less than one-quarter of 
drug outlets, where many people in rural communities first seek care in Kenya, had malaria 
RDTs. Limited malaria RDT availability at drug outlets is likely reflective of both a lack of 
regulatory guidance for point-of-service diagnostic testing and limited customer demand. 
Moreover, only one-third of dispensers asked about malaria symptoms or requested a 
prescription before dispensing antimalarials to pregnant women. The most important factor 
associated with malaria testing of pregnant women was the availability of diagnostic capacity at 
the point of service. The study demonstrated the need to increase the availability of malaria 
diagnostic services, particularly among drug outlets. To increase malaria diagnostic testing at the 
drug-outlet level, regulatory action and implementation of pilot projects should be a priority. A 
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clear diagnostic testing policy for the private sector is a crucial first step toward facilitating 
successful strategies that create awareness and demand for malaria testing before treatment in 
rural communities, including evidence-based educational initiatives and behavior change 
interventions in Kenya. 
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TABLE 1 
Characteristics by health facilities and drug outlets 
Characteristics Health facilities Drug outlets 
 N = 51 % N = 39 % 
Facility managing authority 
 Government 44 86.3 0 0.0 
 Mission 2 3.9 0 0.0 
 Private 5 9.8 39 100.0 
Facility type 
 Hospital 4 7.8 – – 
 Health center 19 37.3 – – 
 Dispensary 28 54.9 – – 
Total health facilities 51 100.0 – – 
 Registered pharmacy – – 9 23.1 
 Informal drug shop – – 13 33.3 
 General shop – – 17 43.6 
Total drug outlets – – 39 100.0 
Patient encounter method Patient interviews Simulated clients 
 N = 209 % N = 147 % 
Pregnancy status     
 Nonpregnant 111 53.1 72 49.3 
 First trimester 22 10.5 37 25.3 
 Second or third trimester 76 36.4 38 26.0 
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TABLE 2 
Provider malaria diagnostic knowledge between health facility and drug outlet providers 
 Overall Health facilities Drug outlets  
 N = 112 % 95% CI N = 
75 
% 95% CI N = 
37 
% 95% CI P value 
Recognition of clinical symptoms 
 Fever 100 89.
3 
(83.5, 
95.0) 
70 93.
3 
(87.8, 98.9) 30 81.
1 
(68.2, 
94.0) 
P = 0.04 
 Chills 65 58.
0 
(47.9, 
68.2) 
55 73.
3 
(61.6, 85.1) 10 27.
0 
(12.4, 
41.6) 
P < 
0.001 
 Headache 84 75.
0 
(66.4, 
83.6) 
64 85.
3 
(76.4, 94.3) 20 54.
1 
(37.7, 
70.4) 
P < 
0.001 
 Vomiting 82 73.
2 
(64.4, 
82.0) 
64 85.
3 
(76.7, 93.9) 18 48.
6 
(32.2, 
65.1) 
P < 
0.001 
 Body ache 66 58.
9 
(49.0, 
68.9) 
51 68.
0 
(55.8, 80.2) 15 40.
5 
(24.4, 
56.7) 
P = 0.01 
Frequency of treatment based on clinical suspicion 
 Always 19 17.
0 
(10.1, 
23.9) 
8 10.
7 
(4.0, 17.3) 11 29.
7 
(14.7, 
44.8) 
0.037 
 Regularly 13 11.
6 
(5.1, 18.1) 7 9.3 (1.8, 16.9) 6 16.
2 
(4.1, 28.3) 
 Sometimes 56 50.
0 
(39.6, 
60.4) 
43 57.
3 
(44.3, 70.3) 13 35.
1 
(19.4, 
50.8) 
 Never 24 21.
4 
(12.6, 
30.2) 
17 22.
7 
(11.2, 34.1) 7 18.
9 
(6.0, 31.8) 
Use parasitological testing 75 67.
0 
(56.6, 
77.3) 
63 84.
0 
(73.1, 94.9) 12 32.
4 
(17.0, 
47.8) 
< 0.001 
 Microscopy 50 44.
6 
(32.9, 
56.4) 
44 58.
7 
(43.4, 73.9) 6 16.
2 
(4.1, 28.3) < 0.001 
 RDT 60 53.
6 
(42.4, 
64.7) 
51 68.
0 
(54.8, 81.2) 9 24.
3 
(10.2, 
38.4) 
< 0.001 
Correct malaria diagnosis knowledge* 
104 
92.
9 
(88.0, 
97.7) 
73 97.
3 
(93.7, 
100.0) 
31 83.
8 
(71.7, 
95.9) 
P = 0.01 
CI = confidence interval; RDT = rapid diagnostic test. 
* Correct malaria diagnosis is defined as the utilization of microscopy or RDT, or clinical diagnosis when diagnostic 
testing is unavailable. 
TABLE 3 
Malaria diagnostics practice in health facilities as observed through exit interviews stratified by facility type 
 Overall Hospital Health center Dispensary  
N % 95% CI N % 95% CI N % 95% CI N % 95% CI 
P 
value 
Tested for 
malaria 
209 – – 
1
8 – – 
8
3 – – 
1
0
8 – – – 
 Yes 
160 
76
.6 
(64.9, 
88.3) 
1
6 
88.
9 
(68.2, 
100.0) 
7
5 
90
.4 
(77.9, 
100.0) 
6
9 
63
.9 
(46.0, 
81.8) 
0.02 
 No 
48 
23
.0 
(8.0, 
38.0) 2 
11.
1 
(0.0, 
31.8) 8 
9.
6 (0.0, 25.2) 
3
8 
35
.2 
(10.7, 
59.7) 
 Don’t know 1 0. (0.0, 0 0.0 – 0 0. – 1 0. (0.0, – 
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5 1.4) 0 9 2.7) 
Malaria test 
results 160 – – 
1
6 – – 
7
5 – – 
6
9 – – – 
 Positive 
151 
94
.4 
(90.4, 
98.3) 
1
4 
87.
5 
(68.3, 
100.0) 
7
0 
93
.3 
(87.3, 
99.4) 
6
7 
97
.1 
(93.6, 
100.0) – 
 Negative 
3 
1.
9 
(0.0, 
4.5) 2 
12.
5 
(0.0, 
31.7) 1 
1.
3 (0.0, 3.6) 0 
0.
0  – 
 Don’t know 
6 
3.
8 
(0.7, 
6.8) 0 0.0 – 4 
5.
3 (0.0, 10.8) 2 
2.
9 
(0.0, 
6.4) 
– 
Test location 
160 – – 
1
6 – – 
7
5 – – 
6
9 – – 
– 
 Outpatient 
clinic 28 
17
.5 
(5.6, 
59.4) 0 0.0 – 3 
4.
0 (0.0, 10.3) 
2
5 
36
.2 
(13.3, 
59.2) 
– 
 Laboratory 
131 
81
.9 
(69.6, 
94.1) 
1
6 
10
0.0 – 
7
2 
96
.0 
(89.7, 
100.0) 
4
3 
62
.3 
(38.8, 
85.9) 
– 
 Pharmacy 
1 
0.
6 
(0.0, 
1.9) 0 0.0 – 0 
0.
0 – 1 
1.
4 
(0.0, 
4.4) 
– 
No diagnostic 
test 49 
23
.3 – 2 
11.
1 – 
1
8 
21
.7 – 
5
7 
52
.3 – 
– 
 Correct 
clinical 
diagnosis* 28 
57
.1 
(37.2, 
77.1) 0 0.0 – 4 
50
.0 (3.3, 96.7) 
2
4 
61
.5 
(40.1, 
82.6) 0.45 
 Incorrect 
diagnosis† 21 
42
.9 
(22.9, 
62.8) 2 
10
0.0 – 4 
50
.0 (3.3, 96.7) 
1
5 
38
.5 
(17.0, 
59.9) – 
Correct malaria 
diagnosis 188 
90
.0 
(85.2, 
94.7) 
1
6 
88.
9 
(68.2, 
100.0) 
7
9 
95
.2 
(90.4, 
99.9) 
9
3 
86
.1 
(79.2, 
93.0) 0.20 
CI = confidence interval. 
* Correct clinical diagnosis indicates women presenting with fever, multiple symptoms, and/or were pregnant with 
symptom(s) at facilities without diagnostic capacity. 
† Incorrect diagnosis indicates patients treated for malaria without diagnostic testing at facilities where it was 
available or without clinical presentation if at a facility with no diagnostic capacity. 
TABLE 4 
Predictors of malaria parasitological testing in health facilities with confirmed diagnostic capacity 
Predictor N 
% 
Crude 
OR 
95% CI 
P 
value 
Adjusted 
OR 
95% CI 
P 
value 
Facility type 151 – – – – – – – 
 Health center or hospital 
80 
53.0 
4.3 
(0.8, 
21.6) 
0.08 3.0 
(0.6, 
15.5) 
0.19 
 Dispensary (reference) 71 47.0 – – – – – – 
Malaria symptoms at patient presentation 
 0–1 104 68.9 3.0 (1.0, 8.7) 0.05 3.0 (1.0, 9.7) 0.06 
 2 or more (reference) 47 31.1 – – – – – – 
Providers completed malaria diagnostic training in prior 5 years    
 Yes 
55 36.4 0.2 
(0.03, 
0.8) 0.02 
0.2 
(0.04, 
1.0) 
0.05 
 None (reference) 96 63.6 – – – – – – 
CI = confidence interval; OR = odds ratio. 
TABLE 5 
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Malaria assessment practice in drug outlets observed via simulated clients stratified by pregnancy status 
 Overall WOCBA or first 
trimester 
Relative: second or third 
trimesters 
 
 N % 95% CI N % 95% CI N % 95% CI P 
value 
Symptoms 7
7 
– – 38 – – 39 – – – 
 Any inquiry 2
5 
32.
5 
(21.6, 
43.3) 
15 39.5 (23.2, 55.7) 10 25.6 (11.3, 40.0) 0.20 
  Specific 1
2 
15.
6 
(7.1, 24.1) 4 10.5 (0.3, 20.7) 8 20.5 (7.3, 33.8) 0.23 
   Fever 7 9.1 (1.7, 16.5) 6 15.8 (3.7, 27.9) 1 2.6 (0.0, 7.8) 0.02 
   Chills 3 3.9 (0.0, 8.3) 3 7.9 (0.0, 16.9) 0 0.0 – – 
   Headache 1
0 
13.
0 
(5.7, 20.2) 8 21.1 (7.5, 34.6) 2 5.1 (0.0, 12.4) 0.05 
   Nausea 6 7.8 (0.7, 14.9) 4 10.5 (0.3, 20.7) 2 5.1 (0.0, 12.4) 0.30 
   Pain 3 3.9 (0.0, 8.3) 2 5.3 (0.0, 12.7) 1 2.6 (0.0, 7.8) 0.55 
 Prescription 4 5.2 (0.0, 11.5) 1 2.6 (0.0, 8.0) 3 7.7 (0.0, 16.4) 0.17 
 Diagnostic test or test 
inquiry 
4 5.2 (0.0, 11.5) 2 5.3 (0.0, 12.7) 2 5.1 (0.0, 12.4) 0.35 
Any malaria diagnostic 
inquiry 
2
6 
33.
8 
(22.4, 
45.2) 
16 42.1 (25.7, 58.5) 10 25.6 (11.3, 40.0) 0.12 
CI = confidence interval; WOCBA = women of childbearing age. 
SUPPLEMENTAL TABLE 1 
Predictors of any malaria diagnostic practice in drug outlets 
Predictor N 
% 
Crude 
OR 
95% CI P value Adjusted OR 95% CI P value 
Facility type 68 – – – – – – – 
 Registered pharmacy 18 26.5 2.4 (0.6, 9.9) 0.22 2.4 (0.6, 10.0) 0.22 
 Informal drug outlet 26 38.2 3.3 (1.0, 10.8) 0.05 2.5 (0.7, 9.6) 0.17 
 General shop 
(reference) 
24 
35.3 
– – – – – – 
Malaria in pregnancy training* 
 Yes 6 8.8 4.2 (1.1, 16.3) 0.04 3.0 (0.6, 14.9) 0.18 
 None (ref) 62 91.2 – – – – – – 
CI = confidence interval; OR = odds ratio. 
* Refers to training conducted within the past 5 years. 
